Compare Cardinal Health Inc (CAH) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Equinor ASA — how do they compare? Cardinal Health Inc trades at $228.9 (market cap $53.89B), while Equinor ASA trades at $35.68 (market cap $83.20B). The key difference: Equinor ASA is the larger of the two by market cap, and Equinor ASA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| CAH | EQNR | |
|---|---|---|
Market Cap | $53.89B | $83.20B |
Sector | Health | Energy |
52-Week High | $239.71 | $42.40 |
52-Week Low | $146.04 | $22.41 |
Enterprise Value | $58.87B | $94.96B |
Dividend Yield | 0.89% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Equinor (EQNR) trades at $36.06, up 6.31% with a bullish technical outlook despite mixed earnings. The stock shows strong profitability with 37.45% gross margins and attractive valuation metrics including a P/E of 16.32 and EV/EBITDA of 2.37. Recent strategic moves include expanding Norwegian Continental Shelf operations through $410M Troll field investment and acquiring BP's Bay du Nord stake, positioning for production growth.
EQNR presents a balanced opportunity with solid fundamentals and strategic growth initiatives, though declining revenue and net income trends warrant monitoring. Analyst sentiment is mixed with 30% buy ratings, while technical indicators suggest near-term strength. Key risks include volatile energy prices and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
